ABBOTINDIA - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.5
| Stock Code | ABBOTINDIA | Market Cap | 55,849 Cr. | Current Price | 26,273 ₹ | High / Low | 37,000 ₹ |
| Stock P/E | 36.0 | Book Value | 2,247 ₹ | Dividend Yield | 2.00 % | ROCE | 44.9 % |
| ROE | 34.5 % | Face Value | 10.0 ₹ | DMA 50 | 26,515 ₹ | DMA 200 | 27,747 ₹ |
| Chg in FII Hold | 0.08 % | Chg in DII Hold | -0.07 % | PAT Qtr | 395 Cr. | PAT Prev Qtr | 376 Cr. |
| RSI | 46.5 | MACD | -175 | Volume | 8,128 | Avg Vol 1Wk | 8,410 |
| Low price | 25,150 ₹ | High price | 37,000 ₹ | PEG Ratio | 2.02 | Debt to equity | 0.04 |
| 52w Index | 9.48 % | Qtr Profit Var | 7.60 % | EPS | 730 ₹ | Industry PE | 32.5 |
Abbott India (ABBOTINDIA) shows moderate potential for swing trading. Technical indicators are mixed: RSI at 46.5 and MACD negative (-175) suggest weak momentum, while price is near 50DMA support. Fundamentals are strong with high ROCE (44.9%), ROE (34.5%), and low debt (0.04). Valuation is slightly expensive (P/E 36 vs industry 32.5). The optimal entry price is near 25,200–25,500 ₹ (recent support). If already holding, consider exiting near 27,500–28,000 ₹, close to 200DMA resistance, unless momentum improves.
✅ Positive
- 📈 Strong ROCE (44.9%) and ROE (34.5%), showing excellent efficiency.
- 💹 EPS at 730 ₹, reflecting strong profitability.
- 💰 Dividend yield at 2.00%, providing income support.
- 📊 Low debt-to-equity ratio (0.04), reducing financial risk.
⚠️ Limitation
- 📉 RSI at 46.5 and MACD negative (-175), showing weak momentum.
- 📊 Price below 200DMA (27,747 ₹), indicating medium-term weakness.
- 📉 Valuation slightly stretched (P/E 36 vs industry 32.5).
- 📊 PEG ratio (2.02) suggests expensive valuation relative to growth.
📰 Company Negative News
- 📉 Slight decline in DII holding (-0.07%), showing reduced domestic institutional interest.
🌟 Company Positive News
- 📈 Quarterly PAT growth (395 Cr vs 376 Cr, +7.6%).
- 📊 Increase in FII holding (+0.08%), showing foreign investor confidence.
🏭 Industry
- 📊 Industry PE at 32.5, slightly lower than Abbott India’s 36, highlighting mild overvaluation.
- 📈 Pharma sector showing stable demand and profitability growth.
📌 Conclusion
Abbott India is fundamentally strong with excellent efficiency metrics and low debt, but technicals show weakness. It can be considered for short-term swing trades with entry near support (25,200–25,500 ₹) and exit near resistance (27,500–28,000 ₹). Long-term investors may find value, but short-term traders should be cautious of weak momentum.
Would you like me to extend this with a pharma sector outlook or a peer comparison to refine the swing trade view?